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anticoagulation that was either suspended 8-12 days pre PRB or replaced by low
molecular weight heparin (not given one day pre procedure). PRB complications: 30,4%
minor asymptomatic complications detected by routine ultrasound and 4,6% hadmajor
complications (surgical or radiological intervention and/or blood products requirement).
Risk factors: pre PRB hemoglobin levels<10 g/dL and diastolic blood pressure>90
mmHgwere significant risk factors. Abnormal PFA 100wasn’t statistically significant.
DDAVP complications:Mean sodiumdecline was 0,963,4mEq/L. 2 patients had
hyponatremia without neurological symptoms: one dropped from 128 to 124mEq/L and
another one had a sodiumdecrease of 12mEq in 24 hours.None of the patients had a
cardiovascular event after dosage (up to onemonth). Table 1:
N = 65 Range
AGE 556 13,3 30-84
GENDER 43 males (66%) 22
females (34%)
KIDNEY TYPE 36 native (55,4%)
GLOMERULI Mean 10,74Median 10 0-41
PASSES 1 = 22 (34%)2 = 36 (55%)
3 = 7 (11%)
NEEDLE 14G = 11 (17%)
16G = 54 (83%)
PLATELET/mm3 201.049,236 71.110,142 75.3 – 413 x103
HB PRE (g/dL) 116 2,2 8,1-17
HB POST (g/dL) 10,56 2,2 2,5-16,1
GFR (MDRD4, ml/min) 27,256 22,28 2,1-102
BPs pre(mmHg) 143,666 32,8 100-212
BPd pre(mmHg) 81,806 9,5 60-99
Sodium pre (mEq/L) 138,126 3,69 128-145
Sodium post (mEq/L) 136,626 3,98 124-144
Hb: haemoglobin; GFR: glomerular filtration rate; BPs: systolic blood pressure;
BPd: diastolic blood pressure.
CONCLUSIONS: Single dose DDAVP pre PRB is safe and can be used in patients with
higher risk of hemorrhagic complications, such as uremia.
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INTRODUCTION:Veltassa is a novel potassium binder that has recently been licensed
to treat chronic hyperkalaemia. Its use as an acute treatment for hyperkalaemia or in
dialysis patients as a bridgingmeasure is unreported. Following its recent addition to
our unit’s formulary for acute treatment at 8.4g OD, we share our experience of the
drug, and its use in treating hyperkalaemia and for bridging in patients on dialysis
whilst access is being (re-)established.
METHODS: Each use of Veltassa is registered in our unit with patient demographics
for audit and clinical governance purposes. A list of patients given the drug over four
months was collated and reviews of patient notes were then performed. Demographic,
medical and biochemical data was recorded, as was episodic information and
indication for the use of the drug.
RESULTS: 120 patient episodes were identified, of which 15 were excluded due to
insufficient available data. Baseline demographics of the cohort of 105 patients: The
mean age of the cohort was 57 years, with 55% beingmale. The prevalence of diabetes
was 47%, hypertension 57%. 49% of patients were undergoing haemodialysis, 8%
peritoneal dialysis, 18% had a renal transplant, 12%were pre-dialysis and 13% had an
AKI. In total 181 doses of Veltassa were administered (68 x1 doses, 18 x 2 doses, 10 x 3
doses, 4 x 4 doses, 5 x =/>5 doses). Of the 105 patient episodes, there were no reports of
adverse events to Veltassa other than one discontinuation due to nausea. The outcomes
of Veltassa use are given in the table below.
Furthermore, of the 44 patients in total that needed repair or re-establishment of
definitive dialysis access, 11 (25%) were sent home and subsequently brought back to
ambulatory services to have their procedure done the next day, thus avoiding hospital
admission.
CONCLUSIONS:Our experience suggests that Veltassa is a well-tolerated agent and
has allowed for safe management of both dialysis and non-dialysis patients. Given our
experience is a retro-spective review of real world use, it is not possible to say that
achieved outcomes were due specifically to Veltassa. In many instances other
potassium lowering treatments were also given (e.g. insulin/dextrose) whilst in other
cases the desired outcome may still have been achieved without Veltassa or even any
treatment. However, our experience suggests that Veltassa has a role for acute use in
renal patients, to safely delay/reduce the number of temporary dialysis line insertions
and unscheduled dialysis sessions in a tertiary renal unit.
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INTRODUCTION: Although transitioning between RRTmodalities is common, data
on it are scarce. INTEGRATED is an international consortium aiming at improved
understanding of quantitative and qualitative aspects of transitioning.We aimed at
exploring the experience of patients transitioning from a home based to an in-center
modality using a qualitative inductive approach.
METHODS: Patients who transitioned RRTmodality were purposively selected. Semi-
structured interviews were performed by one female researcher, recorded and
transcribed verbatim. Data analysis was performed consistent with Charmaz’
constructivist approach of grounded theory and supported by NVivo10 (QSR
International).
RESULTS: 14 patients (78 %male, average age of 60.5 years (range: 27-84))
participated. The conditions of the transitioning process impacted the participants’
experience, resulting in divergent experiences and associated emotions. Not all
participants experienced a loss of control due to the therapy-related changes (paradox
of control). Some felt tied down and having lost independence, whereas others
regained control as they felt relieved from responsibility. Whether patients experienced
not of this paradox of control was related to the patient having (1) experienced a fit of
HDwith their personal life-style, (2) a frame of reference, (3) a certain level of care
requirement, (4) insight in the underlying reasons for transitioning, and (5) trust in the
health care providers. Appreciation of self-esteem, fear for the unknown and the future
were however common themes.
CONCLUSIONS:Combined with the collective perspective that preparation and
initiation of in- center dialysis therapy is emotionally fraught, care teams need to offer
ample opportunities to elicit patient’s knowledge and fears, dispel myths and forge
connections with other patients. A visit to the dialysis unit can alleviate anxiety.
Interventions that facilitate a sense of control need to be grounded in the meaning the
disorder has for the person and its impact on their sense of self.
SP099 COMPLICATIONS AND RISKS OF PERCUTANEOUS RENAL
BIOPSY
Lada Trajceska1, Gjulshen Selim1, Irena Rambabova Busletik1,
Aleksandar Sikole1, Galina Severova1, Igor Nikolov1, Pavlina Vidimliska Dzekova1,
Goce Spasovski1, Vesna Ristovska1, Ladislava Grcevska1
1University Clinic of nephrology, Skopje, Republic of Macedonia
INTRODUCTION: Biopsy is performed in native and transplant kidneys and is
generally considered as a safe procedure. In this study we evaluated the renal biopsy
complications and bleeding risk factors in one nephrology facility.
METHODS:We conducted a three-year retrospective study on patients who
underwent renal biopsy between January 2014 until December 2016. Strict written
biopsy protocol was followed. Clinical and laboratory data were obtained frommedical
histories. Complications were categorized as minor and major according to the need of
blood transfusions. Minor complications included macrohematuria and/or hematoma
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